title: Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.
abstract: Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine oxidase (MAO) type B. Like other similar propargylamine inhibitors, rasagiline binds covalently to the N5 nitrogen of the flavin residue of MAO, resulting in irreversible inactivation of the enzyme. Therapeutic doses of the drug which inhibit brain MAO-B by 95% or more cause minimal inhibition of MAO-A, and do not potentiate the pressor or other pharmacological effects of tyramine. Metabolic conversion of the compound in vivo is by hepatic cytochrome P450-1A2, with generation of 1-aminoindan as the major metabolite. Rasagiline possesses no amphetamine-like properties, by contrast with the related compound selegiline (Deprenyl, Jumex, Eldepryl). Although the exact distribution of MAO isoforms in different neurons and tissues is not known, dopamine behaves largely as a MAO-A substrate in vivo, but following loss of dopaminergic axonal varicosities from the striatum, metabolism by glial MAO-B becomes increasingly important. Following subchronic administration to normal rats, rasagiline increases levels of dopamine in striatal microdialysate, possibly by the build-up of β-phenylethylamine, which is an excellent substrate for MAO-B, and is an effective inhibitor of the plasma membrane dopamine transporter (DAT). Both of these mechanisms may participate in the anti-Parkinsonian effect of rasagiline in humans. Rasagiline possesses neuroprotective properties in a variety of primary neuronal preparations and neuron-like cell lines, which is not due to MAO inhibition. Recent clinical studies have also demonstrated possible neuroprotective properties of the drug in human Parkinsonian patients, as shown by a reduced rate of decline of symptoms over time.
authors.affiliation: Departments of Molecular Pharmacology, The Bruce Rappaport Faculty of Medicine, and the Rappaport Institute for Research in the Medical Sciences, Technion-Israel Institute of Technology, Haifa 31096, Israel.
authors.forename: John P M
authors.initials: JP
authors.lastname: Finberg
keywords: Parkinson’s disease; cheese effect; dopamine; monoamine oxidase; neuroprotection
references.citation: Arch Neurol. 2002 Dec;59(12):1937-43
references.pmid: 12470183
references.citation: Lancet. 2005 Mar 12-18;365(9463):947-54
references.pmid: 15766996
references.citation: Mod Probl Pharmacopsychiatry. 1983;19:170-6
references.pmid: 6408405
references.citation: J Neurosci. 1992 May;12(5):1977-99
references.pmid: 1578281
references.citation: Br J Pharmacol. 1999 Feb;126(4):997-1002
references.pmid: 10193780
references.citation: J Med Chem. 2004 Mar 25;47(7):1767-74
references.pmid: 15027868
references.citation: Inflammopharmacology. 2003;11(2):175-81
references.pmid: 15035819
references.citation: J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9
references.pmid: 15573406
references.citation: Blood Vessels. 1987;24(5):261-70
references.pmid: 3620709
references.citation: J Neural Transm. 1988;74(1):29-42
references.pmid: 3171572
references.citation: Neuropharmacology. 2005 Mar;48(3):406-16
references.pmid: 15721173
references.citation: Br J Pharmacol. 1981 May;73(1):65-74
references.pmid: 6793119
references.citation: Mov Disord. 2008 Nov 15;23(15):2194-201
references.pmid: 18932271
references.citation: J Neurochem. 1994 Jul;63(1):108-17
references.pmid: 8207420
references.citation: J Neural Transm Suppl. 1996;48:95-101
references.pmid: 8988465
references.citation: Eur J Pharmacol. 2003 Jul 11;472(3):173-7
references.pmid: 12871751
references.citation: Lancet. 1977 Feb 26;1(8009):439-43
references.pmid: 65560
references.citation: Neurosci Lett. 2003 May 29;343(1):17-20
references.pmid: 12749987
references.citation: Neuropharmacology. 2002 Dec;43(7):1110-8
references.pmid: 12504917
references.citation: Adv Neurol. 2001;86:385-93
references.pmid: 11554000
references.citation: Neuroscience. 1988 May;25(2):439-56
references.pmid: 3399053
references.citation: J Neurochem. 1971 Jan;18(1):1-6
references.pmid: 5102425
references.citation: J Neural Transm Suppl. 2006;(70):309-19
references.pmid: 17017546
references.citation: FASEB J. 2005 Nov;19(13):1899-901
references.pmid: 16148027
references.citation: J Neural Transm Suppl. 1990;29:119-29
references.pmid: 2193105
references.citation: Br J Pharmacol. 2001 Jan;132(2):500-6
references.pmid: 11159700
references.citation: J Neural Transm (Vienna). 2007;114(6):801-5
references.pmid: 17417741
references.citation: Mov Disord. 2008;23 Suppl 3:S509-14
references.pmid: 18781677
references.citation: Neuroscience. 2002;114(4):825-35
references.pmid: 12379239
references.citation: Adv Biochem Psychopharmacol. 1972;5:393-408
references.pmid: 5066229
references.citation: Science. 1985 Oct 11;230(4722):181-3
references.pmid: 3875898
references.citation: Br J Pharmacol. 1982 Sep;77(1):13-21
references.pmid: 6127132
references.citation: Neuroscience. 1996 Feb;70(3):755-74
references.pmid: 9045087
references.citation: J Neurochem. 1990 Dec;55(6):1827-37
references.pmid: 2172461
references.citation: Psychopharmacology (Berl). 1992;106 Suppl:S21-3
references.pmid: 1546134
references.citation: Clin Ther. 2007 Sep;29(9):1825-49
references.pmid: 18035186
references.citation: J Neurochem. 1995 Sep;65(3):1213-20
references.pmid: 7643100
references.citation: Mov Disord. 2008;23 Suppl 3:S515-20
references.pmid: 18781678
references.citation: Lancet. 1990 Jul 21;336(8708):183
references.pmid: 1973501
references.citation: J Clin Pharmacol. 2005 Aug;45(8):878-94
references.pmid: 16027398
references.citation: Neurobiol Dis. 2007 Jan;25(1):35-44
references.pmid: 17055733
references.citation: Neuroreport. 1998 Mar 9;9(4):703-7
references.pmid: 9559942
references.citation: N Engl J Med. 2009 Sep 24;361(13):1268-78
references.pmid: 19776408
references.citation: J Neural Transm Suppl. 1996;48:45-59
references.pmid: 8988461
references.citation: FASEB J. 2004 Sep;18(12):1471-3
references.pmid: 15247150
references.citation: J Neural Transm Suppl. 1998;52:279-85
references.pmid: 9564628
references.citation: J Neurochem. 1996 Oct;67(4):1532-9
references.pmid: 8858937
references.citation: Adv Neurol. 1999;80:495-9
references.pmid: 10410762
references.citation: Mol Pharmacol. 2000 Jan;57(1):2-12
references.pmid: 10617673
references.citation: Mov Disord. 2008;23 Suppl 3:S599-612
references.pmid: 18781681